Please enable Javascript
Kerri Fitzgerald
Articles by Kerri Fitzgerald
As Liver Cancer Rates, Mortality Continue to Rise, Advocacy and Policy Efforts Are Important
Kerri Fitzgerald
ISGIO 2023
|
January 23, 2024
While liver cancer is the third deadliest cancer in the world, there are still unmet needs regarding the disease.
Read More
New PET Imaging Agent Can Predict Response to CAR T-Cell Therapy
Kerri Fitzgerald
SNMMI
|
September 21, 2023
The approach may help inform clinical decision-making early in treatment.
Read More
Phase 2 Study Supports Radionuclide Alpha Therapy in Patients With Advanced Neuroendocrine Tumors
Kerri Fitzgerald
SNMMI
|
August 24, 2023
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Read More
Study: New AI Scan Strategy Can Cut Radiation Exposure in Half
Kerri Fitzgerald
SNMMI
|
June 30, 2023
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to ...
Read More
Myelofibrosis Associated With Subsequent Development of Multiple Myeloma
Kerri Fitzgerald
Oncology
|
September 26, 2023
A study published in the European Journal of Haematology found that a diagnosis of primary myelofibrosis (MF) or ...
Read More
Radiographic Osteoarthritis Predicts Patient Satisfaction with Contralateral Knee Replacement
Kerri Fitzgerald
Osteoarthritis
|
May 2, 2023
In patients with an unsatisfactory response to first knee replacement, the best predictor of achieving a satisfactory ...
Read More
Systematic Review Compares Allogeneic Hematopoietic Cell Transplant Versus Gene Therapy in Sickle Cell Disease
Kerri Fitzgerald
ASH Annual Meeting 2020
|
August 29, 2023
Sickle cell disease (SCD) shortens life expectancy and leads to morbidity. Recent advancements in allogeneic ...
Read More
Zeta Globin Gene Expression May Lead to Therapy for Alpha Thalassemia Major
Kerri Fitzgerald
ASH Annual Meeting 2020
|
August 29, 2023
Alpha-globin mutations are common, and the number and type of mutated alleles will determine the severity of subsequent ...
Read More
Long-Term Data Support AMT-060 Gene Therapy in Hemophilia B
Kerri Fitzgerald
ASH Annual Meeting 2020
|
August 25, 2023
At the all-virtual 62nd ASH Annual Meeting & Exposition, researchers presented data from an ongoing phase I/II trial ...
Read More
Denosumab Versus Alendronate for Osteoporosis in Patients Receiving Long-Term Glucocorticoids
Kerri Fitzgerald
Osteoporosis
|
July 3, 2023
A study published as part of the American College of Rheumatology Annual Meeting compared denosumab versus alendronate ...
Read More
Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape
Kerri Fitzgerald
Oncology
|
July 5, 2023
Ankit Kansagra, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center ...
View More
Study Identifies Four Features That Impact Survival in Patients with Multiple Myeloma and COVID-19
Kerri Fitzgerald
COVID-19
|
July 5, 2023
A study published in Blood identified the following factors as predictive of worse outcomes for patients with multiple ...
Read More
Romosozumab Improves Hip, Lumbar Spine BMD, But Treatment Sequencing Impacts Outcomes
Kerri Fitzgerald
Osteoporosis
|
August 1, 2023
Romosozumab produces “substantial” bone mineral density (BMD) gains at the total hip and lumbar spine within one ...
Read More
Does the Addition of Ixazomib to Lenalidomide and Dexamethasone Improve Survival in MM?
Kerri Fitzgerald
Oncology
|
July 5, 2023
A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to ...
Read More
Carfilzomib or Bortezomib for Triplet Combination Therapy for Multiple Myeloma?
Kerri Fitzgerald
Oncology
|
July 5, 2023
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the ...
Read More
Survival Outcomes with Maintenance Therapy Versus Observation for Multiple Myeloma
Kerri Fitzgerald
Oncology
|
July 5, 2023
Maintenance therapy increases survival in patients with multiple myeloma (MM) compared with observation, according to a ...
Read More
FDA Approves Retevmo® for RET-Mutated Lung, Thyroid Cancers
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
Read More
FDA Approves Lynparza® Plus Avastin® Combo for Gynecologic Cancers
Kerri Fitzgerald
Oncology
|
August 31, 2023
The U.S. Food and Drug Administration (FDA) approved Lynparza® (olaparib) in combination with Avastin® (bevacizumab) ...
Read More
FDA Approves Targeted Treatment for Lung Cancer Along With Companion Diagnostic
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell ...
Read More
Addition of Tislelizumab to Chemotherapy in Frontline Setting Improves Survival for Lung Cancer
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...
Read More
Load More